As one of the pioneers of gene therapy, Asklepios BioPharmaceutical, Inc. (AskBio) was content to stay independent despite attracting much attention from big pharma, but has now joined the Bayer AG group with both companies insisting that the Research Triangle Park, NC-based biotech's independence will be enhanced not extinguished.
AskBio Declares Independence After Bayer Acquisition
Will Not Be Hamstrung By Bureaucracy
The gene therapy specialist's CEO Sheila Mikhail tells Scrip she is excited to be getting access to the German group's late-stage clinical and operational expertise while keeping AskBio's entrepreneurial culture and carrying on as an autonomous company on an arm’s-length basis.
More from Gene Therapies
• By
Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.
• By
The company posted positive initial results from the Heart-2 trial in HeFH and CAD, with strong LDL cholesterol lowering and a clean safety profile.
• By
Adstiladrin sales hit €70m in first full year on the market
• By
Bharat Biotech is the latest entrant in India’s cell and gene therapy space, joining majors like Intas Pharma, Sun Pharma, Cipla and Dr. Reddy’s. An indigenously developed CAR-T cell therapy launched last year, what is driving growing interest and success in cell and gene therapies?